Zoom imageBetter vision: Dr. Andreas Sachse (left) and Dr. Georg Grötzbach (right) are developing a new treatment that targets the cause of wet macular degeneration. It stops new blood vessels from growing in the eye. They use the test chart to monitor clinical success in subjects worldwide.
The active substance VEGF Trap-Eye, developed jointly by Bayer HealthCare and Regeneron Pharmaceuticals for the treatment of certain eye diseases, has shown positive results in a Phase II study in patients with diabetic macular edema (DME).
The primary endpoint of the study – a statistically significant improvement in visual acuity over 24 weeks compared to the standard of care in DME – laser treatment of the macula, or yellow spot – was met.